via EPFL
Peptides represent a billion-dollar market in the pharmaceutical industry, but they can generally only be taken as injections to avoid degradation by stomach enzymes. Scientists at EPFL have now developed a method to generate peptides that resist enzymatic degradation and can be taken orally.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions. Several peptides are used as drugs such as insulin, which controls the metabolism of sugar, and cyclosporine, which suppresses organ rejection after transplants. More than 40 peptides are already approved as drugs, generating revenues in the billions. There are several hundreds of peptide-based medications currently in clinical trials.
But almost none of these drug-peptides can be taken orally. Since peptides are an important part of food, the stomach and intestines harbor countless enzymes that can degrade them, meaning that most peptide-based medication do not survive the passage through the gastrointestinal tract.
Hope to generate more stable peptides came from “cyclic” peptides, whose ends are joined together by chemical bridges making them more stable than linear ones because their backbones are less flexible and thus harder to attack by enzymes. In 2018, the research group of Christian Heinis at EPFL developed a peptide format termed double-bridged peptides, where peptides are cyclized by two chemical bridges that provide even higher stability. Despite its success, most such peptides were not sufficiently stable to survive the enormous enzymatic pressure found in the gastrointestinal tract.
Now, Heinis’s group has developed a new method that identifies among billions of double-bridged peptides those that bind a disease target of interest and survive enzymes of the gastrointestinal tract. The method is published in Nature Biomedical Engineering, and involves three steps.
First, billions of genetically encoded random peptide sequences are cyclized by two chemical bridges that impose conformational constraints onto the peptides’ backbones so that they are more difficult to attack by enzymes.
Second, this library of peptides is exposed to enzymes from cow intestine to eliminate all those peptides that are not stable.
In the third and last step, the scientist dip target proteins into the pool of surviving peptides to fish out those that bind to the wanted disease target. “It’s a bit like searching a needle in a haystack, and this method makes this easy,” says Heinis.
With this method, the researchers have succeeded for the first time in evolving target-specific peptides that can resist breakdown in the gastrointestinal tract. For example, they gave mice a lead peptide that inhibits thrombin – an important anti-thrombosis target – in the form of a pill. The peptide remained intact in the stomach and intestines, and even though it reached the blood stream in rather small quantities, most of it remained fully intact across the entire gastrointestinal tract. This is a key step towards engineering oral peptide drugs.
Heinis’s group is now applying the new method to develop oral peptides that act directly on gastrointestinal targets, meaning that they don’t need to travel into the blood stream. “We are focusing on chronic inflammatory diseases of the gastrointestinal tract like Crohn’s disease and ulcerative colitis as well as bacterial infections,” says Heinis. “We have already succeeded in generating enzyme-resistant peptides against the interleukin-23 receptor, an important target of these diseases, which affect millions of patients worldwide without any oral drug available.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Oral peptides
- AKTIS ONCOLOGY ANNOUNCES PRESENTATION AT THE OLIGONUCLEOTIDE & PEPTIDE THERAPEUTICS (TIDES USA) CONFERENCE 2024
Aktis Oncology, a biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announces an oral presentation at the ...
- Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it ...
- Vietnam Peptide Therapeutics Market Size, Trends, Growth Status, Share, Research, and Forecast to 2024 to 2032
According to the latest report by Report Ocean, titled this “Vietnam Peptide Therapeutics Market” Report gives evaluation and insights primarily based on authentic consultations with necessary gamers ...
- Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure
Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of car ...
- Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
In April 2024, Entera submitted to the Endocrine Society Annual Meeting (ENDO 2024) pharmacokinetic (PK) and early PD data from a Phase 1 study evaluating an unmodified PTH (1-34) peptide and a new ...
Go deeper with Google Headlines on:
Oral peptides
[google_news title=”” keyword=”oral peptides” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Peptide-based medications
- Peptide-based hydrogel shows promise for a wide range of tissue and organ repair
Combining biomedical finesse and nature-inspired engineering, a uOttawa-led team of scientists has created a jelly-like material that shows great potential for on-the-spot repair to a remarkable range ...
- A look at peptide products to protect against diseases and insects
Peptides are among the most-promising platforms for new biological-based products that protect horticulture and field crops against diseases and insect pests.
- Vietnam Peptide Therapeutics Market Size, Trends, Growth Status, Share, Research, and Forecast to 2024 to 2032
According to the latest report by Report Ocean, titled this “Vietnam Peptide Therapeutics Market” Report gives evaluation and insights primarily based on authentic consultations with necessary gamers ...
- QULIPTA(TM) (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across all frequencies, including episodic and chronic. Expanded ...
- QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first ...
Go deeper with Google Headlines on:
Peptide-based medications
[google_news title=”” keyword=”peptide-based medications” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]